NCI-2019-01887

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer

This Phase 1 study evaluates AGEN1181, an immunotherapy medicine, for individuals with advanced cancer. They're examining how it works on its own and also when combined with another immunotherapy drug called AGEN2034. By testing these treatments, they aim to determine if they're safe and whether using them together could be more effective in treating advanced cancer.

immunotherapy medicine: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03860272

Clinical Trial Site: Sinai

To see all available clinical trials click here.